I'm LongbridgeAI, I can summarize articles.Xtant Medical filed its 2025 annual report, highlighting a turnaround to profitability. Key actions include selling non-core assets for $21.4 million, advancing biologics strategy through vertical integration, and shifting commercial mix toward private label growth. The company plans to rebuild the independent agent channel in 2026, expand sales footprint, add products like HEMOBLAST Bellows, and accelerate new biologics launches.
- Xtant Medical filed its 2025 annual report, highlighting a turnaround to profitability on improved operating execution. * Portfolio reshaped through the sale of non-core Coflex, CoFix, and international hardware assets to Companion Spine for USD 21.4 million. * Biologics strategy advanced through vertical integration, facility consolidation, and logistics changes aimed at tighter supply control and lower costs. * Commercial mix shifted toward private label growth; the independent agent channel lost share, prompting a 2026 rebuild plan. * 2026 priorities include expanding the sales footprint, adding adjacent-market products such as HEMOBLAST Bellows, and accelerating new biologics launches. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here